BioIVT acquires Cypex to boost portfolio
Drug Discovery World
AUGUST 9, 2022
This technology enables the expression of human drug-metabolizing enzymes in bacteria, without requiring large modifications to the proteins.? . Cypex’s product portfolio contains more than 115 recombinant enzymes, including CYPs, UGTs, CES, and AOX, and companion chemicals and media.
Let's personalize your content